Bayer Sees China Approval In Two Years Of Extra Use For Stroke Drug
This article was originally published in PharmAsia News
A Bayer AG executive said the firm expects Chinese approval within the next two years of an expanded indication for its anticlotting drug, Xarelto (rivaroxaban), to prevent strokes and not just treat them.
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.